On October 30th Dr. Janet Woodcock, Director of CDER at the FDA testified before the House Committee on Energy and Commerce, Subcommittee on Health to share her concern on drug manufacturing gradually moving outside the United States.

The FDA believes that advanced manufacturing technologies could enable U.S.-based pharmaceutical manufacturing to regain its competitiveness with China and other foreign countries, and potentially ensure a stable supply of drugs critical to the health of U.S. patients. Examples of some cross-cutting advanced manufacturing technologies include continuous manufacturing and 3D printing. Advanced manufacturing technology, which FDA supports through its Emerging Technology Program, has a smaller facility footprint, lower environmental impact, and more efficient use of human resources than traditional technology.

Click here to read the full testimony